Minerva Neurosciences, Inc. (NERV) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Current obligations | 3.96M USD | Liabilities, Current |
| Cash and equivalents | 24.65M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 50.62M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $3.96M | $24.65M | $50.62M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $4.48M | $32.66M | $45.41M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $2.29M | $82.30M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $2.67M | $12.29M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $2.53M | $15.25M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $1.95M | $17.29M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $2.84M | $21.36M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $4.48M | $26.53M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $4.20M | $30.88M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $2.83M | $34.82M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $3.34M | $40.91M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $3.35M | $46.90M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $1.91M | $51.80M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $2.50M | $35.98M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $1.38M | $36.09M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $2.20M | $40.22M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $3.41M | $49.75M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $3.25M | $54.95M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $2.82M | $60.76M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $3.08M | $65.59M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $4.44M | $74.21M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $3.36M | $80.14M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $3.16M | $25.36M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $5.39M | $32.52M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $7.40M | $32.25M | $3.00M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $7.12M | $30.04M | $7.48M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $6.63M | $21.41M | $24.44M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $9.90M | $37.91M | $22.03M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $7.59M | $27.84M | $41.45M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $6.90M | $30.61M | $48.56M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $3.61M | $50.23M | $37.76M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $3.87M | $87.30M | $10.31M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $5.02M | $68.69M | $39.80M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $7.91M | $45.13M | $75.87M | (m) | (m) | (m) |
| 2017-12-31 | (m) | $6.84M | $26.05M | $102.11M | (m) | (m) | (m) |
| 2017-09-30 | (m) | $8.72M | $36.25M | $96.68M | (m) | (m) | (m) |
| 2017-06-30 | (m) | $14.59M | $50.19M | $27.38M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $12.99M | $68.89M | $16.46M | (m) | (m) | (m) |
| 2016-12-31 | (m) | $9.69M | $82.98M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $10.10M | $91.85M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $6.24M | $88.67M | $8.39M | (m) | (m) | (m) |
| 2016-03-31 | (m) | $6.97M | $34.82M | $9.82M | (m) | (m) | (m) |
| 2015-12-31 | (m) | $5.32M | $14.28M | $17.92M | (m) | (m) | (m) |
| 2015-09-30 | (m) | $3.21M | $16.84M | $20.65M | (m) | (m) | (m) |
| 2015-06-30 | (m) | $3.81M | $21.74M | $13.65M | (m) | (m) | (m) |
| 2015-03-31 | (m) | $4.43M | $52.20M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $3.51M | $18.55M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $3.18M | $23.64M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $10.05M | $480.01K | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $2.14M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $1.41M | $1.82M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | $1.10M | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | $1.48M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $200.31K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |